UNSPSC 51173222: Casanthranol/docusate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173222 Casanthranol/docusate, a Commodity code, represents a narrow pharmaceutical product line — a stool-softening agent combination — that state and local procurement offices do not actively solicit in isolation. Recent state and local opportunities tagged to this code reflect broader drug-testing, pharmacy benefit management, and generic pharmaceutical supply initiatives rather than procurement of casanthranol/docusate as a standalone line item. The code shows little relevant recent activity aligned with its nominal scope; the three recent opportunities on record (Collin County's offender drug-testing RFP, Texas HHS Commission's direct-to-manufacturer prescription RFI, and Minnesota MMCAP's generic pharmaceuticals cooperative purchasing RFP) address specimen collection services, pharmacy benefit program strategy, and multi-source generic drug supply respectively, none of which center on this specific laxative formulation.

State and local health and human services agencies, cooperative purchasing alliances, and county criminal justice departments represent the issuing bodies most active in pharmaceutical procurement, though casanthranol/docusate appears to be purchased, if at all, as a minor line item within larger formulary or generic drug contracts rather than as a standalone commodity. Activity is concentrated in Texas and Minnesota based on the recent posting dates (July 2026, April 2026, and January 2026), but the geographic and issuing-body signals reflect general pharmaceutical procurement capacity rather than demand for this specific product. Firms pursuing this code should expect opportunities to surface primarily through cooperative purchasing vehicles (such as MMCAP) or state Medicaid pharmacy benefit solicitations, where casanthranol/docusate would compete as a generic equivalent within multi-source drug supply agreements, rather than through direct state or local RFPs naming the product by code or trade name.